These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8793601)

  • 21. Lack of pantoprazole drug interactions in man: an updated review.
    Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
    Int J Clin Pharmacol Ther; 1996 Jun; 34(6):243-62. PubMed ID: 8793611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of pantoprazole in man.
    Huber R; Hartmann M; Bliesath H; Lühmann R; Steinijans VW; Zech K
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S7-16. PubMed ID: 8793599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Proton pump inhibitors: Pantoprazole].
    Takeuchi K; Hase S
    Nihon Rinsho; 2002 Feb; 60 Suppl 2():655-60. PubMed ID: 11979865
    [No Abstract]   [Full Text] [Related]  

  • 24. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man.
    Schulz HU; Hartmann M; Steinijans VW; Huber R; Lührmann B; Bliesath H; Wurst W
    Int J Clin Pharmacol Ther Toxicol; 1991 Sep; 29(9):369-75. PubMed ID: 1834592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers.
    Jovanović D; Kilibarda V; Maksimović M
    Pharmazie; 2001 Oct; 56(10):800-2. PubMed ID: 11683127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers.
    Tanaka M; Yamazaki H; Ryokawa Y; Hakusui H; Nakamichi N; Sekino H
    Int J Clin Pharmacol Ther; 1996 Oct; 34(10):415-9. PubMed ID: 8897077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction.
    De Mey C; Meineke I; Steinijans VW; Huber R; Hartmann M; Bliesath H; Wurst W
    Int J Clin Pharmacol Ther; 1994 Feb; 32(2):98-106. PubMed ID: 8004366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No influence of pantoprazole on the pharmacokinetics of phenytoin.
    Middle MV; Müller FO; Schall R; Groenewoud G; Hundt HK; Huber R; Bliesath H; Steinijans VW
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S72-5. PubMed ID: 8793606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioequivalence studies: single vs multiple dose.
    Steinijans VW; Sauter R; Jonkman JH; Schulz HU; Stricker H; Blume H
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S31-6. PubMed ID: 1601529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pantoprazole-induced recurrent anaphylactic shock.
    Fardet L; Izzedine H; Ciroldi M; Tiev KP; Cabane J
    Am J Gastroenterol; 2002 Nov; 97(11):2933. PubMed ID: 12425583
    [No Abstract]   [Full Text] [Related]  

  • 31. ["Mirror, mirror on the wall which is the best proton pump inhibitor of all?"].
    Labenz J; Petersen KU; Rösch W; Koelz HR
    Z Gastroenterol; 2003 Nov; 41(11):1123. PubMed ID: 14648385
    [No Abstract]   [Full Text] [Related]  

  • 32. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.
    Shin JM; Sachs G
    Biochem Pharmacol; 2004 Dec; 68(11):2117-27. PubMed ID: 15498502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Recent topics on important drugs for H. pylori eradication: Pantoprazole sodium].
    Okazaki K; Mori S; Tahashi K
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():354-60. PubMed ID: 16363559
    [No Abstract]   [Full Text] [Related]  

  • 34. [Drug interactions. Proton pump inhibitors II].
    Zaigler M
    Internist (Berl); 1998 Sep; 39(9):978-9. PubMed ID: 9788120
    [No Abstract]   [Full Text] [Related]  

  • 35. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S45-50. PubMed ID: 1601531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992 Aug; 30(8):287-90. PubMed ID: 1526691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proton pump inhibitors: new drugs and indications.
    Mears JM; Kaplan B
    Am Fam Physician; 1996 Jan; 53(1):285-92. PubMed ID: 8546054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1990 Mar; 28(3):105-10. PubMed ID: 2318545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S59-62. PubMed ID: 1601533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers.
    Murdoch RD; Zussman B; Schofield JP; Webber DM
    J Clin Pharmacol; 2004 Sep; 44(9):1046-53. PubMed ID: 15317832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.